Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 10/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 10/20 | 0.41 |
| ▸ | PDE1A | P54750 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 4/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23555503 | 0.89 | PDE1A (0.40) | PDE1BPDE1CPDE1ASMN1; SMN2MEN1 | |
| SCHEMBL23555301 | 0.87 | PDE1A (0.38) | PDE1BPDE1CPDE1ASMN1; SMN2MEN1 | |
| SCHEMBL25068823 | 0.87 | TP53 (0.39) | KITLMNA | |
| SCHEMBL23555303 | 0.85 | PDE1A (0.44) | PDE1BPDE1CPDE1ASMN1; SMN2MEN1 | |
| SCHEMBL23555449 | 0.84 | PIK3CD (0.32) | KITLMNA | |
| SCHEMBL23555576 | 0.83 | GRM2 (0.36) | PDE1BPDE1CPDE1ASMN1; SMN2MEN1 | |
| SCHEMBL23555578 | 0.83 | GRM2 (0.34) | PDE1BPDE1CPDE1AMEN1KMT2A | |
| SCHEMBL23555619 | 0.82 | GRM2 (0.36) | PDE1BPDE1CPDE1ASMN1; SMN2KDM4E | |
| SCHEMBL23555534 | 0.82 | ALDH1A1 (0.41) | PDE1BPDE1CPDE1ASMN1; SMN2MEN1 | |
| SCHEMBL23555319 | 0.80 | PDE1B (0.45) | PDE1BPDE1CPDE1ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2021127071-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | ZC3HAV1, HDAC11, CXCR1 | PDE1B 3860/4885PDE1C 3479/4885PDE1A 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.